Avandia panel says diabetes drug should stay on market


July 14, 2010

Avandia panel says diabetes drug should stay on market

Shocker from the FDA advisory panel: it voted Avandia should stay on the market despite the fact it increases the risk for heart attack. Total vote count: 20 for continued marketing with restrictions and new labeling, 12 voted for withdrawal from the market, 1 abstained.

History of Avandia

CBS: As committee members debate whether the diabetes drug Avandia should be pulled from the market, Dr. Jon LaPook reports the FDA is deeply divided.

Comparing Avandia to Vioxx

2007 Avandia warnings strengthened by the FDA

2007 Another warning by the FDA on Avandia

Publisher: Salient News